Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years

NCT04551547 is registered in ClinicalTrials.gov with Sinovac Research and Development Co., Ltd. as lead sponsor.

NCT NCT04551547
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04551547 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blinded, Placebo-Controlled, Phase Ⅰ/Ⅱ Clinical Trial, to Evaluate the Safety and Immunogenicity of the SARS-CoV-2 Inactivated Vaccine (Vero Cell) in Healthy Population Aged 3-17 Years
Lead sponsor
Sinovac Research and Development Co., Ltd.
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 2020
Completion date
February 8, 2023
Enrollment
552 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19